Study aid only. Verify against current guidelines before clinical use.

All 1,600+ trial summaries

Trials · Leukemias · CML

DasaHIT trial

La Rosée P et al, J Clin Oncol, 2026; PMID: 43024850

Summarized and reviewed by Veli Bakalov, MD · Updated

Malignant HematologyLeukemiasCML2026
Background
Phase 3, multicentre, randomized (German CML Study Group). N=289. Chronic-phase CML; 80% first-line (n=232), remainder second- or later-line. Tests intermittent dasatinib to reduce cumulative toxicity (notably pleural effusion).
Results
Interventions and follow up: Arm A: dasatinib 100 mg daily, 5 days on / 2 days (weekend) off (n=142)
Arm B: dasatinib 100 mg once daily continuous (n=147)
Primary endpoint: co-primary: MMR at 24 mo (non-inferiority, margin 15%) and cumulative toxicity score
mFollow up: NR (24-mo landmark analysis)
Results: MMR 24 mo (all): 78% vs 81%; non-inferiority met (P=.009)
MMR 24 mo (2L+): 24% lower with intermittent dosing; non-inferiority not met
Cumulative toxicity score: no significant difference in grade 2–4 toxicities (co-primary not met)
HRQoL: improved, mainly in 1L pts, favoring intermittent arm
Adverse events
Grade 2–4 (any): no significant difference between arms
Pleural/pericardial effusion: 8% vs 16%; P=.0464 (post hoc)
Conclusions
Weekend drug holiday dasatinib was non-inferior to continuous dosing for 24-month MMR, at least in first-line CP-CML, and halved pleural/pericardial effusions in a post hoc analysis. Not supported for second- or later-line patients.
Key Limitations
Toxicity co-primary endpoint (novel cumulative score) not met; effusion benefit is post hoc. Wide 15% NI margin. Comparator is 100 mg daily, whereas 50 mg daily (Naqvi et al) is increasingly used and not compared. Small 2L+ subgroup. Open-label. Long-term outcomes (MR4.5, TFR eligibility) not reported.
Clinical Context
Dasatinib 100 mg daily is the labeled 1L dose (DASISION); pleural effusion is its key toxicity. Dose-optimization data (dasatinib 50 mg 1L; FDA Project Optimus focus) support lower exposure. DasaHIT adds a schedule-based option for 1L CP-CML patients with tolerability issues; not in label. NCCN/ELN endorse dose reduction for intolerance; intermittent schedule not specifically addressed.
References
La Rosée P et al, J Clin Oncol 2026 (DasaHIT); PMID 43024850
Open in the interactive trials browser View source ↗
HemeOncBuddy Clinical Trials Pivotal trial summaries in hematology and oncology Browse 1,600+ summaries by disease, filter by area or search by drug. Open all trial summaries